169. Menkes disease
6 clinical trials, 6 drugs (DrugBank: 3 drugs), 0 gene, 0 pathway
Searched query = "Menkes disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04337684 (ClinicalTrials.gov) | December 1, 2019 | 1/4/2020 | Long Term Follow-up on Menkes Disease Patients | Long Term Follow-Up and Collection of Historical Control Data on Menkes Disease Patients | Menkes Disease | Drug: Long Term Follow-Up | Cyprium Therapeutics, Inc. | NULL | Enrolling by invitation | N/A | N/A | All | 50 | United States | |
| 2 | NCT04074512 (ClinicalTrials.gov) | August 31, 2019 | 27/8/2019 | Copper Histidinate Treatment for Menkes Disease | Copper Histidinate Treatment for Menkes Disease | Menkes Disease | Drug: Copper Histidinate | Cyprium Therapeutics, Inc. | NULL | Available | N/A | 6 Years | All | NULL | ||
| 3 | JPRN-UMIN000030626 | 2014/11/28 | 28/12/2017 | Investigation on the effectiveness of histidine copper treatment of Menkes disease patients | Menkes disease | Weekly,subcutaneous injection of histidine copper (750microgram once) is performed three times per week.It is continued every week until the end of the research during the research period. | Hamamatsu University School of Medicine | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 2 | Not selected | Japan | |
| 4 | JPRN-UMIN000005259 | 2011/03/03 | 18/03/2011 | Clinical trial of histidine-copper and diethyldithiocarbamate combination therapy for patients with Menkes disease | Menkes disease | give a dose of copper-histidine and diethyldithiocarbamate | Kobe Unniversitu Graduate School of Medicine | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 2 | Not selected | Japan | |
| 5 | NCT00811785 (ClinicalTrials.gov) | February 27, 2009 | 18/12/2008 | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | Menkes Disease;Occipital Horn Syndrome;Unexplained Copper Deficiency | Drug: Copper Histidine | Cyprium Therapeutics, Inc. | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH) | Completed | N/A | 80 Years | All | 93 | Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00001262 (ClinicalTrials.gov) | June 1990 | 3/11/1999 | Copper Histidine Therapy for Menkes Diseases | Early Copper Histidine Therapy in Menkes Disease | Kinky Hair Syndrome | Drug: Copper Histidine | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | N/A | N/A | All | 60 | Phase 1;Phase 2 | United States |